ORTIQCHA VAZN VA SEMIZLIK MAVJUD HOMILADOR AYOLLARDA PREEKLAMPSIYA RIVOJLANISHINING KLINIK VA BIOKIMYOVIY PREDIKTORLARI
Keywords:
homiladorlik, ortiqcha vazn, semizlik, preeklampsiya, klinik prediktorlar, biokimyoviy markerlar, tana massasi indeksi, arterial qon bosimiAbstract
Ushbu tadqiqot ortiqcha vazn va semizlik mavjud homilador ayollarda preeklampsiya rivojlanishini oldindan baholashga xizmat qiluvchi klinik va biokimyoviy prediktorlarni aniqlashga qaratilgan. Unda homiladorlikdan oldingi tana massasi indeksi, akusherlik anamnezi, arterial qon bosimi va hamroh kasalliklar haqidagi ma’lumotlarni biokimyoviy tekshiruv natijalari bilan birgalikda tahlil qilish rejalashtirilgan. Klinik omillar hamda tanlangan biokimyoviy markerlarning mustaqil va birgalikdagi prognostik qiymati baholanadi. Shuningdek, ushbu ko‘rsatkichlarning preeklampsiya rivojlanishi bilan bog‘liqligi ortiqcha vazn va semizlik guruhlarida taqqoslanadi. Tadqiqot orqali xavfni baholash uchun axborotli ko‘rsatkichlar majmuasini shakllantirish hamda homilador ayollarni individual kuzatishni rejalashtirishga ilmiy asos yaratish ko‘zda tutilgan
References
1. Magee L.A., Brown M.A., Hall D.R., et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertension. 2022;27:148–169. DOI: 10.1016/j.preghy.2021.09.008.
2. Sebire N.J., Jolly M., Harris J.P., et al. Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. International Journal of Obesity and Related Metabolic Disorders. 2001;25(8):1175–1182. DOI: 10.1038/sj.ijo.0801670.
3. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation. 2003;111(5):649–658. DOI: 10.1172/JCI17189.
4. O’Gorman N., Wright D., Syngelaki A., et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. American Journal of Obstetrics and Gynecology. 2016;214(1):103.e1–103.e12. DOI: 10.1016/j.ajog.2015.08.034.
5. Rolnik D.L., Wright D., Poon L.C., et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine. 2017;377(7):613–622. DOI: 10.1056/NEJMoa1704559.
6. Zeisler H., Llurba E., Chantraine F., et al. Predictive Value of the sFlt-1 Ratio in Women with Suspected Preeclampsia. New England Journal of Medicine. 2016;374(1):13–22. DOI: 10.1056/NEJMoa1414838.
7. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline NG133. 2019; 2023-yilda yangilangan. Rasmiy tavsiyalar.
8. World Health Organization. Obesity and overweight. Rasmiy axborot sahifasi. Murojaat sanasi: 17.09.2026.
9. Riley R.D., Ensor J., Snell K.I.E., et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368. DOI: 10.1136/bmj.m441.
10. Collins G.S., Reitsma J.B., Altman D.G., Moons K.G.M. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350. DOI: 10.1136/bmj.g7594.
